INVESTOR DEADLINE

Olaplex Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – OLPX

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Olaplex Holdings, Inc. (NASDAQ: OLPX) common stock pursuant and/or traceable to Olaplex’s initial public offering conducted on or around September 30, 2021 (the “IPO”) have until January 17, 2023 to seek appointment as lead plaintiff of the Olaplex class action lawsuit. Captioned Lilien v. Olaplex Holdings, Inc., No. 22-cv-08395 (C.D. Cal.), the Olaplex class action lawsuit charges Olaplex as well as certain of its top executives and directors with violations of the Securities Act of 1933.

If you suffered substantial losses and wish to serve as lead plaintiff of the Olaplex class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-olaplex-holdings-inc-class-action-lawsui ...

You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [e-mail].

CASE ALLEGATIONS: Olaplex manufactures and sells hair care products. Pursuant to its IPO, Olaplex issued more than 73 million shares of its common stock to the public at a price of $21.00 per share for approximate proceeds of more than $1.4 billion to Olaplex.

Olaplex purports to participate in the “prestige segment” of the haircare market, which Olaplex claims is “expected to be the fastest growing segment of the global haircare market from 2020 to 2025.” However, as the Olaplex class action lawsuit alleges, the IPO’s offering documents made false and/or misleading statements and/or failed to disclose that: (i) macroeconomic pressures and competition in the haircare market were more robust than Olaplex had represented to investors; (ii) accordingly, Olaplex was unlikely to maintain its sales and revenue momentum; and (iii) as a result, it was unlikely that Olaplex would be able to achieve the financial and operational growth projected in the IPO’s offering documents.

On September 29, 2022, a Piper Sandler analyst downgraded Olaplex to Neutral from Overweight, stating that her work revealed that “competition and misinformation pose growing risks to [Olaplex].” In addition, the analyst indicated that she anticipated investments in marketing and education were needed to offset the headwinds and that “little room for valuation upside given the risks at play.” On this news, Olaplex’s stock price fell by more than 12%.